EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative sWGS: A New Paradigm for HRD Detection in Ovarian Cancer

Dan Corneliu Jinga, Georgiana Duta-Cornescu iD, Danut Cimponeriu iD, Eirini Papadopoulou, Angeliki Meintani, George Tsaousis iD, Amalia Chirnogea, Irina Bucatariu, Polixenia-Georgeta Iorga iD, Diana Chetroiu, Sorin-Cornel Hosu, Amalia Hogea-Zah und 11 weitere

International Journal of Molecular Sciences · 12.12.2025 · 26 (24) · 11968

DOI: 10.3390/ijms262411968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.12.2025. Verfasst von Dan Corneliu Jinga und 22 weiteren Autor:innen. Beteiligte Einrichtung: Neolife Medical Center, 013975 Bucharest, Romania. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Whole Genome Sequencing, Homologous Recombination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination deficiency (HRD) is a clinically relevant biomarker that predicts sensitivity to PARP inhibitors and enables personalized cancer therapy. Validated local HRD testing solutions are essential to ensure timely and equitable access, ultimately improving treatment outcomes. We evaluated a shallow whole-genome sequencing (sWGS) approach for genomic instability (GI) assessment combined with a 52-gene targeted panel in ovarian cancer. Validation used reference materials and 24 archival samples with prior HRD characterization, comparing performance with the Myriad myChoice® HRD test. A prospective cohort of 124 newly diagnosed ovarian cancer patients was then analyzed. sWGS-derived GI status showed strong concordance with the reference test (95.8% overall agreement; κ = 0.913; NPV 100%, PPV 93.3%). Pathogenic BRCA1/2 variants were detected in 30 patients (24.19%). An additional 22.76% were BRCA1/2-negative but GI-positive, giving an overall HRD prevalence of 47.15%. Platinum sensitivity occurred in 90.0% (18/20) of HRD-positive patients with follow-up. Among 12 patients assessed for PARP-inhibitor response, the overall response rate was 66.7% (95% CI 39.1–86.2) and disease control rate 83.3% (95% CI 55.2–95.3). TP53 alterations were most frequent (62.90%), followed by BRCA1 (19.35%) and BRCA2 (4.83%). Pathogenic variants in other HR-pathway genes (ATM, CHEK2, BRIP1, RAD51C, BARD1) appeared in 9.57% of BRCA-wild-type cases, with heterogeneous GI impact. Two cases showed concurrent BRCA2 variants and microsatellite instability, indicating possible eligibility for anti-PD-1/PD-L1 therapy in addition to PARPi. This first comprehensive analysis of Romanian ovarian cancer patients suggests that integrating sWGS-based genomic instability assessment with BRCA testing can improve HRD detection and reflects the heterogeneity of HR-pathway variants. Preliminary clinical observations were consistent with known HRD-associated treatment responses, although larger studies are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsWhole Genome SequencingHomologous RecombinationHumansFemaleMiddle AgedAgedAdultBRCA1 ProteinBRCA2 ProteinGenomic InstabilityBiomarkers, TumorPoly(ADP-ribose) Polymerase InhibitorsProspective StudiesAged, 80 and over

Stichwörter der Autor:innen

PARP inhibitorsgenomic instabilityhomologous recombination deficiencyovarian cancersWGS

Substanzen

BRCA1 ProteinBRCA2 ProteinBiomarkers, TumorBRCA1 protein, humanPoly(ADP-ribose) Polymerase InhibitorsBRCA2 protein, human

Autor:innen und Institutionen

  • Neolife Medical Center, 013975 Bucharest, Romania.
  • Department of Medical-Surgical and Preventive Disciplines, Faculty of Medicine, Titu Maiorescu University, 040051 Bucharest, Romania.
  • Department of Applied Genetic and Biotechnology, Faculty of Biology, University of Bucharest, 050095 Bucharest, Romania.
  • Genekor Medical S.A., 153044 Athens, Greece.
  • Genekor Medical SRL, 014145 Bucharest, Romania.
  • General Oncology Unit, University Emergency Hospital Bucharest, 050098 Bucharest, Romania.

ORCID-Profile: Georgiana Duta-Cornescu, Danut Cimponeriu, George Tsaousis, Polixenia-Georgeta Iorga, Mircea-Dragos Median, Dana-Lucia Stănculeanu, Raluca Mihaila

Zitieren

APA

Jinga, D. C., Duta-Cornescu, G., Cimponeriu, D., Papadopoulou, E., Meintani, A., Tsaousis, G., Chirnogea, A., Bucatariu, I., Iorga, P. G., Chetroiu, D., Hosu, S. C., Hogea-Zah, A., Median, M. D., Diana, B., Stănculeanu, D. L., Mihaila, R., Nagy, D. S., Motatu, P. E., Eugeniu, T., …, & Truican, A. (2025). Integrative sWGS: A New Paradigm for HRD Detection in Ovarian Cancer. International Journal of Molecular Sciences, 26(24), 11968. https://doi.org/10.3390/ijms262411968

Vancouver

Jinga DC, Duta-Cornescu G, Cimponeriu D, Papadopoulou E, Meintani A, Tsaousis G, et al. Integrative sWGS: A New Paradigm for HRD Detection in Ovarian Cancer. International Journal of Molecular Sciences. 2025;26(24):11968. doi:10.3390/ijms262411968

BibTeX
@article{Jinga2025,
  author = {Jinga, Dan Corneliu and Duta-Cornescu, Georgiana and Cimponeriu, Danut and Papadopoulou, Eirini and Meintani, Angeliki and Tsaousis, George and Chirnogea, Amalia and Bucatariu, Irina and Iorga, Polixenia-Georgeta and Chetroiu, Diana and Hosu, Sorin-Cornel and Hogea-Zah, Amalia and Median, Mircea-Dragos and Diana, Bogdan and Stănculeanu, Dana-Lucia and Mihaila, Raluca and Nagy, Dana-Sonia and Motatu, Pompilia-Elena and Eugeniu, Turcanu and Cristea, Elena-Octaviana and Iaciu, Ion-Cristian and Kubelac, Paul and Truican, Andreea},
  title = {Integrative sWGS: A New Paradigm for HRD Detection in Ovarian Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {24},
  pages = {11968},
  doi = {10.3390/ijms262411968}
}
Kostenlos starten →